About Scancell limited
Scancell Limited: Revolutionizing Cancer Treatment with Innovative Immunotherapies
Scancell Limited is a UK-based biotechnology company that is dedicated to developing innovative immunotherapies for cancer. The company was founded in 1997 by Professor Lindy Durrant and Dr. Richard Goodfellow, who are both experts in the field of cancer immunotherapy.
The mission of Scancell is to revolutionize cancer treatment by harnessing the power of the body's own immune system to fight cancer. The company's approach involves developing novel vaccines that stimulate the immune system to recognize and attack cancer cells.
Scancell's lead product candidate, SCIB1, is a first-in-class DNA vaccine that targets melanoma, a type of skin cancer. SCIB1 has shown promising results in clinical trials, with some patients experiencing long-term remission from their disease.
In addition to SCIB1, Scancell has several other product candidates in development for various types of cancer, including ovarian and lung cancers. These products are based on the same platform technology as SCIB1 and have shown encouraging preclinical results.
One key advantage of Scancell's approach is its ability to target specific antigens on tumor cells while leaving healthy cells unharmed. This targeted approach minimizes side effects and improves patient outcomes compared to traditional chemotherapy or radiation therapy.
Another advantage of Scancell's technology is its potential for combination therapy with other immunotherapies or conventional treatments such as chemotherapy or radiotherapy. This could enhance the effectiveness of these treatments while minimizing their toxicities.
Scancell has also developed a proprietary technology called ImmunoBody®, which allows for rapid development of new vaccines targeting different types of cancers or infectious diseases. This technology uses small antibody fragments called single-chain variable fragments (scFvs) that can be easily modified to target different antigens.
Overall, Scancell Limited represents an exciting opportunity in the field of cancer immunotherapy. With its innovative approach and promising product pipeline, the company is well-positioned to make a significant impact on cancer treatment in the years to come.